Skip to content


Kalydeco (ivacaftor) is a small molecule pharmaceutical. Ivacaftor was first approved as Kalydeco on 2012-01-31. It is used to treat cystic fibrosis in the USA. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator. Kalydeco's patents are valid until 2033-02-27 (FDA).
Trade Name Kalydeco
Common Name Ivacaftor
Indication cystic fibrosis
Drug Class Cystic fibrosis transmembrane regulator (CFTR) protein modulators
Get full access now